ConductScience.org, home

Paper20197387

SB939, a novel potent and orally active histone deacetylase inhibitor with high tumor exposure and efficacy in mouse models of colorectal cancer.

Novotny-Diermayr V and 16 others. Mol Cancer Ther, 2010. Cited by 113 papers, by iCite.

Cite this record

ConductScience Library. SB939, a novel potent and orally active histone deacetylase inhibitor with high tumor exposure and efficacy in mouse models of colorectal cancer. Papers, record 20197387. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/20197387

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
SB939, a novel potent and orally active histone deacetylase inhibitor with high tumor exposure and efficacy in mouse models of colorectal cancer.
PubMed
Journal
Mol Cancer Ther
PubMed
Year
2010
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
113
iCite
Relative citation ratio, by iCite
2.72
iCite
Revised in PubMed
2020-09-30
PubMed

Authors17

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Novotny-Diermayr VVeronica
2Sangthongpitag KKanda
3Hu CYChang Yong
4Wu XXiaofeng
5Sausgruber NNina
6Yeo PPauline
7Greicius GGediminas
8Pettersson SSven
9Liang ALAi Leng
10Loh YKYung Kiang
11Bonday ZZahid
12Goh KCKee Chuan
13Hentze HHannes
14Hart SStefan
15Wang HHaishan
16Ethirajulu KKantharaj
17Wood JMJeanette Marjorie

Source PubMed

Download CSV of authors

Topics18

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Colorectal NeoplasmsMajor topic
Histone Deacetylase InhibitorsMajor topic
Hydroxamic AcidsMajor topic
Administration, Oral
Animals
Antineoplastic Agents
Biological Availability
Female
HCT116 Cells
Humans
Mice
Mice, Inbred BALB C
Mice, Nude
Neoplasms
Treatment Outcome
Tumor Cells, Cultured
Vorinostat
Xenograft Model Antitumor Assays

Source PubMed

Download CSV of topics

Cited by51

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 113 citations.

PMIDTitleJournalYearIn PapersSource
42415186Mapping the Safety Profile of Histone Deacetylase Inhibitors in Children with Cancer.Clin Epigenetics2026https://conductscience.org/library/papers/42415186PubMed
41473577Thermal shift engagement assay for Class IIA histone deacetylase inhibitor screening.Results Chem2025https://conductscience.org/library/papers/41473577PubMed
40805121Epigenetic Therapies in Endocrine-Related Cancers: Past Insights and Clinical Progress.Cancers (Basel)2025https://conductscience.org/library/papers/40805121PubMed
40775761Assessing the selective impact of histone modifying drugs on adenoid cystic carcinoma cells and their stem cell counterparts.BMC Cancer2025https://conductscience.org/library/papers/40775761PubMed
40283883Advanced High-Content Phenotypic Screening to Identify Drugs That Ameliorate the Inhibition of Skeletal Muscle Cell Differentiation Induced by Cancer Cachexia Serum.Pharmaceuticals (Basel)2025https://conductscience.org/library/papers/40283883PubMed
40151421Effects of SB939 are mediated by STAT3 to inhibit breast cancer cell metastasis-related genes.Oncol Lett2025https://conductscience.org/library/papers/40151421PubMed
40027347Synthesis of fluorinated tubastatin A derivatives with bi-, tri-, and tetracyclic cap groups: molecular docking with HDAC6 and evaluation of in vitro antitumor activity.RSC Med Chem2025https://conductscience.org/library/papers/40027347PubMed
39801754Targeting the epigenome with advanced delivery strategies for epigenetic modulators.Bioeng Transl Med2025https://conductscience.org/library/papers/39801754PubMed
39136440Analysis of the effect of HDAC inhibitors on the formation of the HIV reservoir.mBio2024https://conductscience.org/library/papers/39136440PubMed
38465731Discovery of novel anaplastic lymphoma kinase (ALK) and histone deacetylase (HDAC) dual inhibitors exhibiting antiproliferative activity against non-small cell lung cancer.J Enzyme Inhib Med Chem2024https://conductscience.org/library/papers/38465731PubMed
37711592Medicinal chemistry advances in targeting class I histone deacetylases.Explor Target Antitumor Ther2023https://conductscience.org/library/papers/37711592PubMed
36148005Molecular mechanisms of histone deacetylases and inhibitors in renal fibrosis progression.Front Mol Biosci2022https://conductscience.org/library/papers/36148005PubMed
35622308The novel histone deacetylase inhibitor pracinostat suppresses the malignant phenotype in human glioma.Mol Biol Rep2022https://conductscience.org/library/papers/35622308PubMed
34677780Drug target inference by mining transcriptional data using a novel graph convolutional network framework.Protein Cell2022https://conductscience.org/library/papers/34677780PubMed
33999145Study of the antilymphoma activity of pracinostat reveals different sensitivities of DLBCL cells to HDAC inhibitors.Blood Adv2021https://conductscience.org/library/papers/33999145PubMed
33628709Characterizing binding intensity and energetic features of histone deacetylase inhibitor pracinostat towards class I HDAC isozymes through futuristic drug designing strategy.In Silico Pharmacol2021https://conductscience.org/library/papers/33628709PubMed
33266366Structure-Based Inhibitor Discovery of Class I Histone Deacetylases (HDACs).Int J Mol Sci2020https://conductscience.org/library/papers/33266366PubMed
32365701Repurposing Old Drugs into New Epigenetic Inhibitors: Promising Candidates for Cancer Treatment?Pharmaceutics2020https://conductscience.org/library/papers/32365701PubMed
32212730Design, Synthesis, and Biological Evaluation of Quinazolin-4-one-Based Hydroxamic Acids as Dual PI3K/HDAC Inhibitors.J Med Chem2020https://conductscience.org/library/papers/32212730PubMed
32019149Understanding Failure and Improving Treatment Using HDAC Inhibitors for Prostate Cancer.Biomedicines2020https://conductscience.org/library/papers/32019149PubMed

See all 51 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/20197387

GET https://conductscience.org/api/papers/v1/20197387/cited_by?page=2